Nkarta, Inc.

NasdaqGS:NKTX Stock Report

Market Cap: US$166.9m

Nkarta Management

Management criteria checks 3/4

Nkarta's CEO is Paul Hastings, appointed in Feb 2018, has a tenure of 8.5 years. total yearly compensation is $2.98M, comprised of 22.6% salary and 77.4% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $388.94K. The average tenure of the management team and the board of directors is 2.1 years and 6.5 years respectively.

Key information

Paul Hastings

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage22.65%
CEO tenure8.5yrs
CEO ownership0.2%
Management average tenure2.1yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

Analysis Article • Jul 07

Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Nov 22

Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

Summary Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune diseases, despite current market pessimism. NKX019, the lead CAR-NK candidate, shows promising early preclinical results in B cell depletion and is advancing through Ntrust-1 and Ntrust-2 trials. NKTX boasts a strong cash position, providing over three years of operational runway, supporting continued research and development through key upcoming milestones. While clinical data is delayed to 1H 2026 and risks remain high, the current valuation undervalues NKTX’s potential, justifying a positive outlook. Read the full article on Seeking Alpha
Analysis Article • Nov 01

Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jul 15

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 31

Nkarta: Betting On The Turnaround

Summary Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention. Despite risks, NKTX is significantly undervalued with a potential upside; I plan to buy below $2.50 and target a sell at $7.05. Read the full article on Seeking Alpha
Analysis Article • Feb 27

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 02

Nkarta, Inc.: Trying To Find Space In A Crowded Place

Summary Nkarta has ceased development of NKX019 in lymphoma, focusing instead on autoimmune diseases. NKTX has $402.5M in cash and investments, which it estimates will last into late 2027. The name currently trades at less than half of cash. Cell therapy for autoimmune disease is a crowded space, but NKTX's ongoing trials, Ntrust-1 and Ntrust-2, in combination with two investigator sponsored trials, do give it multiple shots on goal. Read the full article on Seeking Alpha
Seeking Alpha • Oct 31

Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)

Summary Nkarta is set to report data from its CAR-NK cell therapy, NKX019, used in a compressed dosing regime in lymphoma patients, in late 2024, possibly with Q3'24 earnings. NKTX seems increasingly focused on the development of NKX019 in autoimmune diseases, with trials of NKX019 in various autoimmune conditions underway already or soon to be underway. The Company faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning chemotherapy. Read the full article on Seeking Alpha
Analysis Article • Sep 10

We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Nkarta ( NASDAQ:NKTX...
Seeking Alpha • Aug 14

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Summary Nkarta, Inc. data from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory large B-cell lymphoma, expected by end of 2024. The global non-Hodgkin's Lymphoma Therapeutics market is expected to grow to $17.5 billion by 2032. NKX019 has a better shot at being effective towards autoimmune disorders, because of several factors like no antigen escape, lower cell burden to go after and no tumor microenvironment. Data from the Ntrust-1 study targeting LN patients and results from Ntrust-2 targeting SSC, myositis and vasculitis, expected in 2025. Read the full article on Seeking Alpha
Seeking Alpha • May 23

Nkarta: A Look Into Q1 Results And Upcoming Catalysts

Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. The success of Nkarta's lead program, NKX019, in clinical trials will be crucial for the company's future and potential revenue generation. Read the full article on Seeking Alpha
Seeking Alpha • Apr 27

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Summary NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in oncology with more data coming mid-year. The work in autoimmune disease is just getting underway in H1'24. Read the full article on Seeking Alpha
Seeking Alpha • Mar 25

Nkarta: NK Cell Therapy Advancement On Two Fronts

Summary Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036. NKX019 is also being used to target patients with autoimmune disorders like Lupus Nephritis; the first patient in the phase 1 study is to be dosed in 1st half of 2024. Nkarta had $250.9 million in cash as of December 31, 2023, to fund its operations into 2026. Despite this cash runway, a public offering of $240 million was expected to close in March 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

Nkarta: Possible Upside From H1 Update, If Positive

Summary NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program. NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of 60% in patients with acute myeloid leukemia. The company's focus on a specific lymphodepletion regimen has shown better safety and durability outcomes, positioning them as a leader in the NK cell therapy space. Read the full article on Seeking Alpha
Analysis Article • Jan 16

Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 04

We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jun 21

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 06

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 20

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Nkarta GAAP EPS of -$0.61

Nkarta press release (NASDAQ:NKTX): Q2 GAAP EPS of -$0.61. Cash and Cash Equivalents: As of June 30, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $415.0 million.
Analysis Article • Jun 09

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 20

Nkarta: A Promising Natural Killer Cell Play

The market has favorably appreciated Nkarta’s recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the actual share price, possibly due to the market’s lack of insight in the highly innovative nature of the science. I give my take on Nkarta’s science, its recent readout, and its competitors. The stock is a long-term buy for me, but I do advise further investment diversificationin similar companies.
Analysis Article • Aug 23

We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 10

Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 25

We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Paul Hastings's remuneration changed compared to Nkarta's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$117m

Mar 31 2026n/an/a

-US$100m

Dec 31 2025US$3mUS$674k

-US$104m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$109m

Mar 31 2025n/an/a

-US$111m

Dec 31 2024US$4mUS$648k

-US$109m

Sep 30 2024n/an/a

-US$111m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$3mUS$624k

-US$118m

Sep 30 2023n/an/a

-US$122m

Jun 30 2023n/an/a

-US$125m

Mar 31 2023n/an/a

-US$119m

Dec 31 2022US$5mUS$600k

-US$114m

Sep 30 2022n/an/a

-US$104m

Jun 30 2022n/an/a

-US$98m

Mar 31 2022n/an/a

-US$93m

Dec 31 2021US$7mUS$576k

-US$86m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$72m

Mar 31 2021n/an/a

-US$102m

Dec 31 2020US$3mUS$560k

-US$91m

Sep 30 2020n/an/a

-US$84m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$27m

Dec 31 2019US$3mUS$543k

-US$21m

Compensation vs Market: Paul's total compensation ($USD2.98M) is above average for companies of similar size in the US market ($USD1.55M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Hastings (66 yo)

8.5yrs
Tenure
US$2,978,038
Compensation

Mr. Paul J. Hastings is Chairman of Specific Biologics Inc. from June 2025. Mr. Hastings had been President of Nkarta, Inc. since February 2018 until July 2024 and serves as its Chief Executive Officer as...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Hastings
CEO & Director8.5yrsUS$2.98m0.23%
$ 388.9k
Nadir Mahmood
President and Principal Accounting & Financial Officer2.1yrsUS$1.40m0.058%
$ 96.2k
Shawn Rose
Chief Medical Officer and Head of Research & Development1.2yrsUS$1.22m0%
$ 0
2.1yrs
Average Tenure

Experienced Management: NKTX's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Hastings
CEO & Director8.5yrsUS$2.98m0.23%
$ 388.9k
Leone Patterson
Independent Director6.3yrsUS$122.29k0%
$ 0
Michael Dybbs
Independent Director7yrsUS$130.29k0%
$ 0
Simeon George
Independent Director6.5yrsUS$113.29k0%
$ 0
Zachary Scheiner
Independent Director6.5yrsUS$118.29k0%
$ 0
Angela Thedinga
Independent Director4.4yrsUS$132.79k0%
$ 0
George Vratsanos
Independent Director2.2yrsUS$119.29k0%
$ 0
Ali Behbahani
Independent Chairman10.8yrsUS$154.79k0%
$ 0
6.5yrs
Average Tenure
50.5yo
Average Age

Experienced Board: NKTX's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/12 06:22
End of Day Share Price 2026/08/12 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nkarta, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William MaughanCanaccord Genuity
Joshua SchimmerEvercore ISI
Emily BodnarH.C. Wainwright & Co.